Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_assertion type Assertion NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_head.
- NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_assertion description "[Despite major advances in the treatment of this highly aggressive disease with potent inhibitors of the BCR-ABL kinase such as dasatinib, patients in remission frequently relapse due to persistent minimal residual disease possibly supported, at least in part, by salutary cytokine-driven signaling within the hematopoietic microenvironment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_provenance.
- NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_assertion evidence source_evidence_literature NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_provenance.
- NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_assertion SIO_000772 25499760 NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_provenance.
- NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_assertion wasDerivedFrom befree-2016 NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_provenance.
- NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_assertion wasGeneratedBy ECO_0000203 NP1247227.RACNv1BCCYOXvEwJs0MoaBwxndsvrezmTJE_IjYquouUQ130_provenance.